#Sinopharm
Explore tagged Tumblr posts
agreenroad · 1 year ago
Text
What If Pfizer Is Chinese Government Controlled? BioNTech Signed MOU With Fosun Pharma - How Many Chinese/US High Tech Connections To Covid 19 Virus And Vaccine?
BioNTech, the subsidiary that manufactures Pfizer’s injections signed a memorandum of understanding with Fosun Pharma Dr. Naomi Wolf: Pfizer is essentially a company controlled by the Chinese government! ‌ BioNTech, the subsidiary that manufactures Pfizer's injections, has signed a memorandum of understanding with Fosun Pharma, one of China's largest CCP-controlledpic.twitter.com/vJnqq0FpZU—

View On WordPress
0 notes
etsyee · 1 year ago
Text
Sinopharm Budapest T-Shirt
Express yourself with ease with Sinopharm Budapest T-Shirt, sinopharm Budapest t-shirts are a symbol of resilience and unity in the face of adversity. These t-shirts not only represent a clothing item, but also carry a strong message of hope and determination. The Sinopharm Budapest t-shirt has become a popular item in recent times, particularly during the current global pandemic.
Buy now: Sinopharm Budapest T-Shirt
Tumblr media
More Post:
Slainte Irish Drink Shirt
You’re Telling Me A Dick Sported These Goods T-Shirt
Visit Store: https://etsyee.com/
0 notes
darkmaga-returns · 3 months ago
Text
by Nicolas Hulscher, MPH
Solely based on the mechanism of action of COVID-19 mRNA injections (instructing cells in various organ systems, including the reproductive system, to produce toxic Spike protein), it can be assumed that COVID-19 genetic injections are not safe for pregnant women and the developing baby. This article will describe key studies that affirm this assumption.
First, it’s important to note that even inactivated virus COVID-19 vaccines (Sinopharm) are not safe for pregnant women. A recent study by Heidary et al, titled Placental Histopathological Changes and the Level of Anti-Spike Antibody After Covid-19 Vaccination During Pregnancy: A Case Series, found that:
Among 20 pregnant women vaccinated with Sinopharm (inactivated virus vaccine), 25% had abnormal histopathological findings in the placenta, including decidual vasculopathy, subchorionic thrombosis, and chronic histiocytic intervillositis. All mothers and neonates, except one pair, were positive for anti-spike antibodies:
8 notes · View notes
didanawisgi · 6 months ago
Text
4 notes · View notes
allthebrazilianpolitics · 1 year ago
Text
Brazilian-developed vaccine against Covid-19 registered by Anvisa
Tumblr media
The new vaccine against Covid-19 developed by the Brazilian company Zalika FarmacĂȘutica has been entered into the National Health Surveillance Agency (Anvisa) this week, Agencia Brasil reported. The drug can be used in people aged 12 and over and is to be administered in two doses, 21 days apart, with boosters after 6 months for those over 18 years of age.
The technology used in the Zalika vaccine is called “recombinant” because its molecules are formed by combining two different sources. In this case, the protein S antigen (spike) -capable of promoting a response from the immune system- and the saponin-based adjuvant allow the mixture to enhance the production of antibodies. This form of production brings greater safety to the pharmaceutical industry, Anvisa explained in a statement.
The new immunizer is the sixth to receive definitive individual registration from Anvisa, in addition to Comirnaty Ipfizer/Wyeth, Comirnaty bivalent (Pfizer), Janssen Vaccine (Janssen-Cila), Oxford/Covishield (Fiocruz and Astra-Zeneca) and Spikevax bivalent vaccines have received this type of authorization. Pfizer/Biontech, Astra-Zeneca, Janssen, Moderna, Sinopharm, and Sinovac also have definitive registration in the form of the Covax Facility consortium.
Continue reading.
9 notes · View notes
digitalmore · 24 days ago
Text
0 notes
gireportstory · 2 months ago
Text
Penicillin Active Pharmaceutical Ingredients Industry Research: Top Five Players Occupy For A Share About 50%
According to our (Global Info Research) latest study, the global Penicillin Active Pharmaceutical Ingredients market size was valued at US$ 1767 million in 2024 and is forecast to a readjusted size of USD 1608 million by 2031 with a CAGR of -1.3% during review period.
Penicillin refers to a class of antibiotics containing penicillin in the molecule, which can destroy the cell wall of bacteria and play a bactericidal role in the breeding period of bacterial cells. It is an antibiotic extracted from Penicillium. Penicillin belongs to ÎČ-lactam antibiotics, and ÎČ-lactam antibiotics include penicillin, cephalosporin, carbapenems, monocyclic, and cephalosporins. Penicillin is a very common antibacterial drug. However, an intradermal test must be performed before each use to prevent allergies. This report focuses on Penicillin Active Pharmaceutical Ingredients.
The Penicillin Active Pharmaceutical Ingredients (API) market is primarily driven by the widespread use of penicillin-based antibiotics in treating bacterial infections. Penicillin remains one of the most commonly prescribed antibiotics due to its effectiveness, affordability, and relatively low side effects. The rising incidence of infectious diseases globally continues to fuel the demand for penicillin APIs, particularly in developing countries where the prevalence of such diseases is higher. Additionally, the increasing focus on improving healthcare access in these regions further boosts the market.
Another significant driver is the ongoing demand for generic antibiotics. As patents for many branded antibiotics expire, generic drug manufacturers are able to produce lower-cost alternatives using penicillin APIs, making antibiotics more accessible to a larger population. Government initiatives aimed at reducing healthcare costs and promoting the use of generics further stimulate this demand, especially in countries with cost-sensitive healthcare systems.
However, the market faces several challenges, particularly with the growing problem of antibiotic resistance. The overuse and misuse of penicillin and other antibiotics have led to the development of resistant strains of bacteria, which reduces the effectiveness of these drugs. Additionally, strict regulatory requirements and quality standards in the production of penicillin APIs create barriers for manufacturers, especially in terms of compliance and cost. Furthermore, fluctuations in the price and availability of raw materials can affect production costs and profitability in the market.
Global key players of Penicillin Active Pharmaceutical Ingredients include United Laboratories, Changsheng Pharma, North China Pharmaceutical, Centrient Pharmaceuticals, Aurobindo Pharma and Sinopharm Weiqida Pharmaceutical, etc. Top five players occupy for a share about 50%. Asia-Pacific is the largest market, with a share about 60%, followed by Americas and Europe. In terms of product, Amoxicillin is the largest segment, with a share over 76%. In terms of application, For Oral is the largest market, with a share over 73%.
"Penicillin Active Pharmaceutical Ingredients" 2025 Breakdown, Data Source, Secondary Sources, Primary Sources, Research Report delivers leading competitors strategic analysis, with micro and macro-economic factors, market trends, future growth scenarios, with pricing analysis. This report provides a holistic overview on Market Current Situations, Key Collaborations, Merger & Acquisitions along with Trending Innovations and New Business Development Policies. A detailed professional report focusing on primary and secondary growth drivers, regional segments, growth share, and geographical analysis of top key players. Penicillin Active Pharmaceutical Ingredients trend analysis with historical data, estimates to 2025 and Compound Annual Growth Rate (CAGR) forecast to 2031.
Top Key Players Covered in Market Report 2025-2031:United Laboratories、Changsheng Pharma、North China Pharmaceutical、Centrient Pharmaceuticals、Aurobindo Pharma、Sinopharm Weiqida Pharmaceutical、Novartis、Qilu Pharmaceutical、Jiangxi Huabang、ACS Dobfar、Jiangxi Fushine Pharmaceutical、CSPC、LKPC、Harbin Pharmaceutical Group Short Description of the Penicillin Active Pharmaceutical Ingredients 2025-2031: Market Overview of Global Penicillin Active Pharmaceutical Ingredients: According to our latest research, the global Penicillin Active Pharmaceutical Ingredients looks promising in the next 6 years. As of 2025, the global Penicillin Active Pharmaceutical Ingredients was estimated at USD Million, and it’s anticipated to reach USD Million in 2031, with a CAGR during the forecast years. This report covers a research time span from 2020 to 2031, and presents a deep and comprehensive analysis of the global Penicillin Active Pharmaceutical Ingredients, with a systematical description of the status quo and trends of the whole market, a close look into the competitive landscape of the major players, and a detailed elaboration on segment markets by type, by application and by region. Global and Regional Analysis:     North America (United States, Canada and Mexico)     Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)     Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)     South America (Brazil, Argentina, Colombia, and Rest of South America)     Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market Segmentation Penicillin Active Pharmaceutical Ingredients report provides an exhaustive 360-degree analysis, by utilizing both primary and secondary research techniques. The research gained comprehensive insights into current market dynamics, pricing trends, developments, supply-demand and evolving consumer behaviors.
On the basis of product type, this report displays the production, revenue, price, market Amoxicillin、Piperacillin、Benzylpenicillin Sodium、Ampicillin、Other
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each For Oral、For InjectionOur method for estimating market size is holistic and multifaceted. We assess vital industry trends, regulatory landscapes, and segment-specific dynamics, evaluating their potential influence on demand projections. Key macroeconomic factors, including price fluctuations, demographic shifts, and changes in demand patterns, are integrated into our calculations. To discover market value, we not only delve deep into the profiles of prominent players and their global market shares but also rely on our frequently updated internal database, enriched with insights and announcements from pivotal market stakeholders.
Some of the Key Questions Answered in this Report:
What is the Penicillin Active Pharmaceutical Ingredients size at the regional and country level
What are the key drivers, restraints, opportunities, and challenges of the Penicillin Active Pharmaceutical Ingredients, and how they are expected to impact the market
What is the global (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa) sales value, production value, consumption value, import and export of Penicillin Active Pharmaceutical Ingredients
Who are the global key manufacturers of the Penicillin Active Pharmaceutical Ingredients? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)
What are the Penicillin Active Pharmaceutical Ingredients opportunities and threats faced by the vendors in the Penicillin Active Pharmaceutical Ingredients?
Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
What focused approach and constraints are holding the Penicillin Active Pharmaceutical Ingredients?
What are the different sales, marketing, and distribution channels in the global industry?
What are the key market trends impacting the growth of the Penicillin Active Pharmaceutical Ingredients?
Economic Impact on the Penicillin Active Pharmaceutical Ingredients and development trend of the Penicillin Active Pharmaceutical Ingredients
What are the Penicillin Active Pharmaceutical Ingredients opportunities, market risk, and market overview of the Penicillin Active Pharmaceutical Ingredients
The content of the study subjects, includes a total of 15 chapters: Chapter 1, to describe Hydrogen Bromide product scope, market overview, market estimation caveats and base year. Chapter 2, to profile the top manufacturers of Hydrogen Bromide, with price, sales, revenue and global market share of Hydrogen Bromide from 2020 to 2025. Chapter 3, the Hydrogen Bromide competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Hydrogen Bromide breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031. Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031. Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and Penicillin Active Pharmaceutical Ingredients forecast, by regions, type and application, with sales and revenue, from 2026 to 2031. Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis. Chapter 13, the key raw materials and key suppliers, and industry chain of Hydrogen Bromide. Chapter 14 and 15, to describe Hydrogen Bromide sales channel, distributors, customers, research findings and conclusion. Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
0 notes
techobaby · 3 months ago
Text
Global General Reagents Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2030
This report studies the General Reagents market, General reagents generally refers to inorganic reagents and organic reagents that can meet standard purity. It is often applied to scientific research, analysis and testing, and synthetic reaction and also used as new materials. According to our (Global Info Research) latest study, the global General Reagents market size was valued at USD 5756.7 million in 2022 and is forecast to a readjusted size of USD 6882.2 million by 2030 with a CAGR of 2.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. General Reagents is widely used in Government & Institutions, Academic, Industry, Pharma and other field. The most proportion of General Reagents is used in Industry and Pharma, and the proportion is about 23% and 23% respectively. North America is the largest consumption place, with a consumption market share nearly 28%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%. Market competition is intense Merck, Thermo Fisher Scientific, VWR (Avantor) and Kanto Chemical, etc. are the leaders of the industry, with about 40% market shares. This report is a detailed and comprehensive analysis for global General Reagents market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets.
Sample Plan: https://www.reportsintellect.com/sample-request/2911807 Key Features: Global General Reagents market size and forecasts, in consumption value ($ Million), sales quantity (MT), and average selling prices (USD/Kg), 2018-2029 Global General Reagents market size and forecasts by region and country, in consumption value ($ Million), sales quantity (MT), and average selling prices (USD/Kg), 2018-2029 Global General Reagents market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (MT), and average selling prices (USD/Kg), 2018-2029 Global General Reagents market shares of main players, shipments in revenue ($ Million), sales quantity (MT), and ASP (USD/Kg), 2018-2023 Inquire Sample : https://www.reportsintellect.com/discount-request/2911807
The Primary Objectives in This Report Are: To determine the size of the total market opportunity of global and key countries To assess the growth potential for General Reagents To forecast future growth in each product and end-use market To assess competitive factors affecting the marketplace This report profiles key players in the global General Reagents market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Thermo Fisher Scientific, VWR (Avantor), Kanto Chemical and FUJIFILM Wako Chemical, etc. This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence. Market Segmentation General Reagents market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. Market segment by Type Organic Reagents Inorganic Reagents Market segment by Application Government & Institutions Academic Industry Pharma Others Major players covered Merck Thermo Fisher Scientific VWR (Avantor) Kanto Chemical FUJIFILM Wako Chemical Xilong TCI Sinopharm Chemical Reagent Junsei Chemical ITW Reagents Tedia Katayama Chemical Nanjing Reagent J&K Scientific Guangzhou Chemical Reagent Factory ChengDu Chron Chemicals SRL Chemical Market segment by region, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe) Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia) South America (Brazil, Argentina, Colombia, and Rest of South America) Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
0 notes
myrawjcsmicasereports · 5 months ago
Text
Rapid progression of angioimmunoblastic t cell lymphoma after Covid-19 vaccination by Iryna Abramenko, MD in Journal of Clinical Case Reports Medical Images and Health Sciences
Abstract
We present the case of a 57-year-old male patient from Ukraine who developed tonsillitis and generalized lymphadenopathy approximately one week after receiving the first dose of the ChAdOx1 (AstraZeneca) anti-SARS-CoV-2 vaccine. A total body computerized tomography scan revealed pronounced lymphadenopathy above and below the diaphragm, and enlargement of the spleen. Histologic examination of the left inguinal lymph node revealed revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved. Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases.
Introduction
SARS-Cov-2 virus infection is widespread throughout the world. By May 2023, the number of infected cases raised to 765,903,278 persons and a total 13,350,530,518 vaccine doses have been administered [1]. Vaccination is an effective mean of preventing infection and the development of severe forms of the disease. Eleven vaccines were recommended by World Health Organization for vaccination: Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, CovoVax (Novavax formulation), Convidecia, Sanofi-GSK; a number of vaccines are under consideration [2]. Oxford-AstraZeneca, CoronaVac, Pfizer-BioNTech, and Moderna were used for vaccination against SARS-CoV-2 in Ukraine [3].
Vaccination leads to the development of protective antiviral immunity [4, 5]. In oncological patients, this may have ambivalent influence on tumor growth. Two cases of spontaneous tumor regression after SARS-Cov-2 vaccination have been described: shrinking of the cervical lymph node and resolution of the diffuse lung lesions in patient with a recurrent primary cutaneous anaplastic large-cell lymphoma one week after having received the first COVID-19 vaccination (BioNTech/Pfizer) [6]; and spontaneous regression of metastatic salivary gland myoepithelial carcinoma in patient one month after vaccination of mRNA-1273 COVID-19 (Moderna) vaccine [7]. Anti-cancer effect of COVID-19 vaccines (a decrease in tumor size, a decrease in the expression of tumor markers (VEGF, Ki-67, MMP-2/9), CD4/CD8 ratio, and metastasis to the vital organs) has been shown in 4T1 mice models [8].
On the other hand, cases of progression of oncohematological diseases after vaccination have also been described. Goldman et al. described rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot [9]. Cavanna et al. presented a case of anaplastic large-cell lymphoma that developed in a patient approximately 10 days after receiving the third dose of the BNT162b2 vaccine and summarized eight additional cases identified in the available literature [10]. There were four cases of diffuse large-B-cell lymphoma [11-13], one case of extranodal NK/T-cell lymphoma [12], one patient with subcutaneous panniculitis-like T-cell lymphoma [14], one case of marginal zone B-cell lymphoma [15] and one primary cutaneous anaplastic large-cell lymphoma  (developed at the SARS-CoV2 vaccine injection site) [16].
In this article, we report a case of angioimmunoblastic T-cell lymphoma developed shortly after SARS-CoV2 vaccination.
Case report
The patient is a 57-year-old Caucasian man with no previous history of disease. On May 6, 2021, he received the first dose of the ChAdOx1 (AstraZeneca). A few days later, he noted a flu-like syndrome and a sore throat. A diagnosis of tonsillitis was established. Antibacterial therapy was ineffective and within two weeks patient noted rapid increase of cervical, axillary, and inguinal lymph nodes. On May, 28, 2021, trephine biopsy of the left inguinal lymph node was performed.
Pathological examination revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. Mitotic figures, single plasma cells, macrophages, neutrophils and eosinophils were present. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Small clusters of CD20-positive cells were found between tumor cells. CD21- and CD23-positive follicular dendritic cells wrapped around postcapillary venules. Conclusion (8.06.2021): morphological changes in the lymph node and the immunophenotype of tumor cells correspond to diagnosis of angioimmunoblastic T cell lymphoma.
CT scan (29.05.2021) revealed pronounced lymphadenopathy above and below the diaphragm (diameters of cervical lymph nodes 10-24 mm, paratracheal lymph nodes 8-18 mm, bifurcation lymph nodes 14-25 mm, right axillary lymph nodes up to 20 mm, left axillary lymph nodes up to 15 mm, inguinal lymph nodes 8-28 mm), enlargement of the spleen (5.8x12.0x11.3 cm).
On June, 11, 2021 patient referred to the hematological department of National Research Center for Radiation Medicine. Complaints of the patient upon admission: fever (up to 380C) in the second half of the day, weakness, severe fatigue, enlargement of tonsils and lymph nodes. At examination: ECOG2 performance status. Weight 72 kg. Height 174 cm. Skin is pale. Peripheral lymph nodes are palpable: submaxillary up to 6 cm, cervical 4-6 cm, axillary up to 4 cm, inguinal up to 4 cm in diameter. The liver is not enlarged. The spleen is not palpable. Breathing is vesicular. Systolic murmur over the cardiac apex. The heart rhythm is correct. Blood pressure is 115/75 mm Hg, heart rate is 80 per min. There are no edema.
Bone marrow aspiration (11.06.2021) showed hypercellular marrow, dysplasia in erythropoiesis and megakariocytopoiesis, absence of blast cells, 5.6% of lymphocytes, no cytological signs of leukemic involvement. Among all nuclear bone marrow cells 1.68% with phenotype CD45dim+CD34+CD7+CD5+CD1a-TdT- were quantified by flow cytometry.
Except high level of blood lactate dehydrogenase (1249 units/L), and C-reactive protein (29.8 mg|L) other results of laboratory test of blood and urine were unremarkable.
Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established, and CHOEP (cyclophosphamide, vincristine, doxorubicin, etoposide and prednisone) regimen was initiated. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved: hemodynamic parameters are stable, peripheral lymph nodes are not palpable, the spleen is not enlarged, and the size of the tonsils has decreased significantly.  At the time of this report the patient continues to be in clinical and hematological remission.
Discussion
The most exciting, intriguing question is: can vaccines induce the development of tumors, in particular, lymphoproliferative diseases?
So far, only the development of fibrosarcomas in cats after vaccination is known. This has been proven for killed adjuvanted virus vaccines (vaccination against rabies and feline leukemia virus). An inflammatory process with the formation of granulomatous nodules, only 5% of which subsequently undergo transformation, preceded tumor development. The interval between vaccine administration and detection of sarcoma varied from 4 months to several years [17]. In human, we found three similar cases in the literature: the development of lymphoma and undifferentiated, pleiomorphic high-grade sarcoma at the site of anti-SARS-CoV-2 vaccine administration [16, 18], and peripheral T-cell lymphoma at the injection site of influenza vaccination [19]. However, the interval between vaccine administration and tumor development was short, which does not fit into the classical scheme for the development of the oncological process (initiation, promotion, progression). Thus, it is unclear whether there is a true association between vaccination and the development of malignancy.
For the case described in this article, progression of preceding lymphoma under the influence of the vaccine seems more likely. Anti-SARS-CoV-2 vaccines cause a powerful immune response and stimulation of T- and B-lymphocytes, as well as the production of numerous cytokines [20]. Cases of post vaccine benign lymphadenopathy are described [21]. Today, AITL is recognized as a neoplasm derived from T-follicular helper cells [22, 23]. Up to 75% of AITL patients had a mutation RHOA G17V that facilitates proliferation and activation of several signaling pathways [24]. Since T-follicular helper cells are one of the main targets of mRNA vaccines [25], the Goldman et al. suggested that their stimulation under the influence of the vaccine can accelerate the development of AITL. In their case the malignant cells of patient had a mutation RHOA G17V that could make them especially sensitive to anti-SARS-CoV-2 vaccines [9]. Unfortunately, molecular genetic studies have not been performed in our patient.
Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases. It will contribute to our better understanding of the possible negative consequences of anti-SARS-CoV-2 vaccination and their prevention as well.
0 notes
saadkhan2917 · 8 months ago
Text
Laboratory Reagents Market Report 2024 - By Size, Report, Growth, Demand, Forecast To 2034
 The Laboratory Reagents market report offered by Reports Intellect is meant to serve as a helpful means to evaluate the market together with an exhaustive scrutiny and crystal-clear statistics linked to this market. The report consists of the drivers and restraints of the Laboratory Reagents Market accompanied by their impact on the demand over the forecast period. Additionally, the report includes the study of prospects available in the market on a global level. With tables and figures helping evaluate the Global Laboratory Reagents market, this research offers key statistics on the state of the industry and is a beneficial source of guidance and direction for companies and entities interested in the market. This report comes along with an additional Excel data-sheet suite taking quantitative data from all numeric forecasts offered in the study.
Get Sample PDF Brochure @ https://www.reportsintellect.com/sample-request/2910555
Key players offered in the market: Merck Thermo TCI American Element Sinopharm Xilongchemical ABCR BOC Sciences Wako-chem Kanto Scientific OEM Glentham Life Sciences
Additionally, it takes account of the prominent players of the Laboratory Reagents market with insights including market share, product specifications, key strategies, contact details, and company profiles. Similarly, the report involves the market computed CAGR of the market created on previous records regarding the market and existing market trends accompanied by future developments. It also divulges the future impact of enforcing regulations and policies on the expansion of the Laboratory Reagents Market.
Scope and Segmentation of the Laboratory Reagents Market
The estimates for all segments including type and application/end-user have been provided on a regional basis for the forecast period from 2024 to 2034. We have applied a mix of bottom-up and top-down methods for market estimation, analyzing the crucial regional markets, dynamics, and trends for numerous applications. Moreover, the fastest & slowest growing market segments are pointed out in the study to give out significant insights into each core element of the market.
Laboratory Reagents Market Type Coverage: - Solvents Acids Standards Dyes Solutions
Laboratory Reagents Market Application Coverage: - Government Academic Industry Pharma Environmental institutions
Regional Analysis:
North America Country (United States, Canada) South America Asia Country (China, Japan, India, Korea) Europe Country (Germany, UK, France, Italy) Other Countries (Middle East, Africa, GCC)
Also, Get an updated forecast from 2024 to 2034.
Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/2910555
The comprehensive report provides:
Complete assessment of all opportunities and threats in the global market.
Laboratory Reagents Market recent advancements and major events.
A thorough study of business policies for the growth of the Laboratory Reagents Market leading players.
Concluding study about the growth plot of Laboratory Reagents Market for upcoming years.
Detailed understanding of Laboratory Reagents Market particular drivers, restraints, and major micro markets.
Favorable impression inside vital technological and market latest trends hitting the Laboratory Reagents Market.
Reasons to Purchase Laboratory Reagents Market Research Report
Develop a competitive approach based on the competitive landscape
Build business strategy by identifying the high growth and attractive Laboratory Reagents market classifications
Identify potential business partners, gaining targets and business buyers
Design financial investment policies based on estimated high potential segments
Prepare management and tactical presentations using the Laboratory Reagents market data
Plan for new product promotion and portfolio in advance
Covid-19 Impact Analysis: Our research analysts are highly focused on the Laboratory Reagents Market covid-19 impact analysis. A whole chapter is dedicated to the covid-19 outbreak so that our clients get whole and sole details about the market ups & downs. With the help of our report the clients will get vast statistics as to when and where should they invest in the industry.
About Us: Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in today's competitive world.
Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.
Contact Us: [email protected] Phone No: + 1-706-996-2486 US Address: 225 Peachtree Street NE, Suite 400, Atlanta, GA 30303
0 notes
schoje · 9 months ago
Text
Em entrevista coletiva transmitida hoje (15), o ministro da SaĂșde, Eduardo Pazuello, confirmou que o presidente Jair Bolsonaro estĂĄ discutindo novos nomes para assumir a posição de titular da pasta. “O presidente estĂĄ pensando em substituição, avaliando nomes. O presidente estĂĄ em tratativas para reorganizar o ministĂ©rio. Enquanto isso nĂŁo for definido, a vida segue normal. Nïżœïżœo estou doente. Quando o presidente tomar sua decisĂŁo faremos a transição correta, como manda o figurino”, declarou. Na coletiva em que fez um balanço da gestĂŁo no combate Ă  pandemia, Pazuello afirmou que nĂŁo deixarĂĄ o ministĂ©rio e que cabe ao presidente Jair Bolsonaro definir se e quando efetuarĂĄ a troca de comando. “Estou Ă  disposição para ajudar todos que vierem aqui. Isso nĂŁo Ă© palavra de despedida. Tenho orgulho de estar Ă  frente da pasta cumprindo missĂŁo. NĂŁo me sinto pressionado por nenhuma notĂ­cia ou fake news. O problema Ă© a pandemia, os Ăłbitos. Apoiar todos os brasileiros - esta Ă© a missĂŁo”, comentou. Vacinas Em meio a crĂ­ticas sobre a gestĂŁo, Pazuello fez um balanço das açÔes contra a pandemia, em especial os esforços de vacinação. Ele afirmou que a pasta prevĂȘ disponibilizar 562,9 milhĂ”es de doses em 2021.  Contudo, 110 milhĂ”es de doses da Oxford/AstraZeneca e 30 milhĂ”es de doses da CoronaVac previstas no cronograma e que jĂĄ tiveram recursos alocados ainda nĂŁo foram efetivamente contratadas, jĂĄ que o dinheiro nĂŁo foi pago. Assim, o nĂșmero de doses efetivamente contratadas atĂ© o momento fica em 422,9 milhĂ”es. Veja abaixo o cronograma de recebimento das vacinas para o ano: IFA Pazuello afirmou que o processo de transferĂȘncia de tecnologia que habilitarĂĄ o Brasil a produzir o Ingrediente FarmacĂȘutico Ativo (IFA) em territĂłrio nacional estĂĄ dois meses adiantado. “JĂĄ temos todos os equipamentos instalados. Os engenheiros quĂ­micos foram capacitados e devemos começar a produção em abril. Com isso, passamos a ter independĂȘncia na produção de vacinas.” Mais doses A equipe do MinistĂ©rio mantĂ©m tambĂ©m tratativas com a farmacĂȘutica Moderna e a Sinopharm - esta ainda em estado inicial - para a compra de mais 13 milhĂ”es de doses, que nĂŁo entraram na soma total apresentada pelo ministro. Programa Nacional de Imunização Pazuello informou que no fim de semana se reuniu com governadores do Nordeste e que as 37 milhĂ”es de doses compradas por eles serĂŁo custeadas pelo governo federal e distribuĂ­das pelo Programa Nacional de Imunização. O titular do ministĂ©rio apresentou uma previsĂŁo de 38 milhĂ”es de doses em março. Neste total estĂŁo oito milhĂ”es de doses da farmacĂȘutica indiana Bharat Biotech, que ainda nĂŁo obteve registro definitivo nem para uso em carĂĄter emergencial junto Ă  AgĂȘncia Nacional de VigilĂąncia SanitĂĄria (Anvisa). O ministro destacou que atĂ© o final do 1Âș semestre o programa de vacinação terĂĄ contemplado todos os pĂșblicos prioritĂĄrios, e que atĂ© 2021 ele poderĂĄ atingir a totalidade dos brasileiros, com exceção daqueles contraindicados para receber a vacina ou sem eficĂĄcia ainda comprovada em testes, como imunodeprimidos, gestantes e crianças. “Vamos vacinar atĂ© o meio do ano grupos prioritĂĄrios e uma boa parte da população. Chegaremos Ă  metade [da população]. E vamos chegar atĂ© o fim de 2021 com toda a população. Com a oferta de vacinas crescendo Ă© provĂĄvel que a velocidade aumente”, ressaltou. Assista na Ă­ntegra *MatĂ©ria atualizada para acrĂ©scimo de informaçÔes durante a coletiva.
0 notes
gamboagarcia · 10 months ago
Text
Gracias de antemano por sus comentarios Se amplia a 22 millones de dosis de vacunas Chinas para México Llegarån 12 millones de Sinopharm que ha sido autorizada en 15 países. Ciudad de México - El secretario de Relaciones Exteriores (SRE), Marcelo Ebrard, informó que el Gobierno de México ha recibido confirmación para la ampliación de hasta 22 millones de dosis de vacunas contra Covid-19 de procedencia china: Sinovac y Sinopharm. Durante... Sigue leyendo: https://www.adiario.mx/orbe/se-amplia-a-22-millones-de-dosis-de-vacunas-chinas-para-mexico/?feed_id=163203&_unique_id=6689819360173
0 notes
darkmaga-returns · 6 months ago
Text
Children’s Health Defense’s The Defender has a blockbuster report. (link in footnote)
“A group of Argentine scientists identified 55 chemical elements—not listed on package inserts—in the Pfizer, Moderna, AstraZeneca, CanSino, Sinopharm and Sputnik V COVID-19 vaccines, according to a study published last week in the International Journal of Vaccine Theory, Practice, and Research.”
“The chemical elements include 11 heavy metals—such as chromium, arsenic, nickel, aluminum, cobalt and copper—which scientists consider systemic toxicants known to be carcinogenic and to induce organ damage, even at low exposure levels.”
ARSENIC in the vaccines? How does that happen? I can’t see how a vaccine assembly line would be accidentally contaminated with arsenic, from other prior uses.
There are extremely important further statements in the Defender article. For example:
“The research builds on a series of studies conducted since 2021 using different analytic techniques to analyze COVID-19 vaccine vials from major manufacturers. Previous studies also identified significant numbers of chemical elements not listed on vaccine labels.”
“Research efforts included a 2022 study by a German working group, including the late pathologist Arne Burkhardt, submitted to the German government; a 2021 study by scientists in England; a 2022 study by Canadian Dr. Daniel Nagase; and a 2023 Romanian study by Dr. Geanina Hagimă.”
These previous studies, which yielded results similar to the findings of the latest Argentine group, flew under the radar.
There is no doubt that toxic chemicals in COVID vaccines is an URGENT issue which needs to be widely known and investigated further—after the vaccinations are halted immediately.
Of course, for a number of reasons I and others have explained for years, the vaccines should never have been launched in the first place.
Warp Speed was one of Trump’s gross exaggerations. It was a lethal project from the beginning. Trump would prefer it to be buried as ancient history. He still claims the kill shot “saved millions of lives.”
Trump’s interim President—he stood aside and let Fauci run the country—eventually made sure the vaccine was mandated.
0 notes
lboogie1906 · 10 months ago
Text
Tumblr media
President Évariste Ndayishimiye (born on June 17, 1968) in Giheta, Burundi. After serving in the Burundi Army, he began studies in law at the UniversitĂ© du Burundi in Bujumbura. His legal education was interrupted by the civil war and ethnic divisions between the Hutu and the Tutsi ethnic groups, which cost at least 300,000 lives during its thirteen years.
He married AngĂ©lique Ndayubaha Ndayishimiye (2003) an economist and the President of the Good Action Foundation “Umugiraneza.” They are the parents of six children.
He was the Interior and Public Security Minister for Burundi, he served as the personal military aide to President Pierre Nkurunziza. He received an LLB from UniversitĂ© Sagesse d’Afrique and chaired the Burundi National Olympic Committee. He became the Secretary-General of The National Council for the Defense of Democracy, a new Burundi political party. In 2018, he was endorsed by President Nkurunziza as his replacement after the incumbent decided not to run for a fourth term.
On June 18, 2020, he was sworn in as the 9th president of Burundi in the capital city of Gitega after winning 68 percent of the national vote in an election marred by violence and the death of Nkurunziza ten days earlier. Opposition leaders claimed the election was rigged but he vowed to “preserve and promote the country’s independence, love, and equitably achieved development. He had four journalists and two human rights defenders released from prison and announced the pardon or early release of more than 5,000 prisoners.
He addressed the UN General Assembly’s 76th session declaring that refugees who had fled the nation were welcome to return. He announced a strategic action plan designed to protect human rights in Burundi and discussed the restoration of peace, security, stability, and social cohesion in this civil war-torn nation.
In a country where the COVID-19 pandemic remains a threat to thousands of Burundi citizens, he rejected vaccines from outside the nation and closed its borders to foreigners he claimed for safety. To protect himself against COVID-19, he did receive sizable doses of the Chinese Sinopharm BIBP vaccine. #africanhistory365 #africanexcellence
0 notes
insights10-marketing · 11 months ago
Text
Tumblr media
China Anemia Therapeutics Market Analysis Report 2022 to 2030
The China Anemia Therapeutics Market is anticipated to experience a growth from $1.19 Bn in 2022 to $2.664 Bn by 2030, with a CAGR of 10.6% during the forecast period of 2022-2030. The aging population's increased risk of anemia from chronic illnesses, the burden of chronic diseases, rising disposable income that drives up healthcare expenditure, and improved awareness and early detection of anemia are the main drivers in China. The China Anemia Therapeutics Market encompasses various players across different segments, including Pfizer, Roche, GlaxoSmithKline (GSK), Novartis, Sanofi, Amgen, Jiangsu Hengrui Medicine, Guangzhou Baiyunshan Pharmaceutical, Sinopharm Group, Shanghai Pharmaceuticals, etc, among various others.
1 note · View note
digitalmore · 25 days ago
Text
0 notes